Fri, Aug 09, 2024
Zydus Lifesciences reports a 31% year-on-year increase in consolidated net profit to ₹1,420 crore for Q1 FY25, driven by robust sales growth. Revenue surged to ₹6,207 crore, up from ₹5,140 crore in the previous year. Strong performance in the US and India markets, along with a strategic focus on sustainable growth and innovation, underscores the company’s positive outlook for the fiscal year. Shares closed 1.91% higher at ₹1,304.
More >
Fri, Jul 19, 2024
Which stocks will be in focus today: Sanstar Ltd, Tata Consumer Products Ltd, Zydus Lifesciences Ltd & Vodafone Idea Ltd? News shares and triggers. Know about Stocks In News.
Thu, Jul 11, 2024
Which stocks will be in focus today Raymond, Bajaj Consumer Care, Zydus Lifesciences Ltd & Mankind Pharma? News shares and triggers. Know about Stocks In News.
Mon, Dec 18, 2023
"Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) a leading discovery-based, global pharmaceutical company, announced today that it has received permission from USFDA, to initiate the Phase II clinical study of NLRP3 inhibitor “ZYIL1” in patients with Parkinson’s disease," Zydus said in a statement on Saturday.
Thu, Aug 31, 2023
The drug firm has received final approval from the US Food and Drug Administration (USFDA) for Isotretinoin Capsules USP (10 mg, 20 mg 30 mg and 40 mg), it said in a statement.
Fri, Aug 11, 2023
Zydus Lifesciences Q1 Results: Zydus Lifesciences Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 1,086.9 crore for the first quarter ended June 30, 2023, driven by strong sales growth from US formulations.
Thu, Apr 06, 2023
Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture and market its generic Acetazolamide tablets used in the treatment of glaucoma.
Sun, Mar 26, 2023
As per the latest enforcement report by the US Food and Drug Administration (USFDA), Zydus Pharmaceuticals (USA) Inc is recalling 21,936 (30 count) and 33,096 (100 count) bottles of Colchicine tablets, which are used to treat gout.
Tue, May 03, 2022
Zydus Lifesciences Ltd announced on Tuesday that the US Food and Drug Administration (USFDA) has given final approval to commercialize its generic version of Bortezomib for injection.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
